Biotech Values

[Mpower]

Dew,

"Sanofi-aventis now expects business EPS1 growth for 2010 to be between 0% and 2% versus 20094 business EPS, at constant exchange rates and barring major unforeseen adverse events. This guidance takes into account generic competition for Ambien CR® in the U.S., possible entry of generics of Taxotere® in the U.S. and the E.U. and further erosion of Lovenox® sales in the U.S."

As I read the statement, on its face, SNY expects "further erosion of Lovenox sales" ...



See Sanofi Quarterly Earnings Release (see page 1 http://en.sanofi-aventis.com/binaries/20101028_Q3_2010_en_tcm28-29489.pdf)